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Abstract 
Introduction: HPV infection has a prime etiologic role in development and progression of cervical cancer,  one of 
the most frequent forms of cancer among women in developing countries. This study was designed to determine the 
most prevalent HPV genotypes in women with normal and abnormal cervical cytology in Iran. Materials and Methods: 
Samples from134 patients, including 127 who attended gynecology clinics and 7 with solid cervical tumors were 
used. All 127 patients underwent routine Pap tests for cytological evaluation and at the same visit a sample of 
cervical epithelial cells was obtained by scraping the cervix osteum. In each case HPV infection was primarily evaluated 
by PCR using GP 5/6 primers and then subtyping was performed in proved infected samples with specific primers 
for HPV 16, 18, 31, 33, 11 and 6. After cytological evaluation, 50 patients with abnormal Pap tests were categorized 
as the abnormal group and the remaining 77 patients  as the normal group. Results: In the normal group, HPV 
infection was established in 10 cases (13% infection rate), while 30 HPV positive cases were discovered in the abnormal 
group (60% infected). The most prevalent genotypes among the infected samples were HPV 16 (76%), HPV18 (12.7%) 
and HPV11/6 (8.5%). Moreover, all 7 tumor samples were positive for HPV general primers of which, 5 samples 
were infected with HPV 16, two were co-infected with HPV16,18 and HPV16,31 genotypes and one was infected with 
HPV 18. Conclusions: Infection with HPV 16 was found to be significantly higher in abnormal group in comparison 
with normal group (42% vs. 11.6%, P value <0.005), likewise HPV18 genotypes were proved to be more prevalent in 
abnormal group (8% vs. 0%, P value <0.05). No significant relation between other HPV genotypes and pathologic 
cervical changes was obtained. According to our study high rates of infection with HPV genotypes in sexually active 
Iranian women makes molecular investigation for HPV16 and 18 very essential in clinical approaches to patients 
with proven dysplasia in their screening tests and also for those patients with borderline (i.e. ASCUS) or incongruous 
pathology reports. Larger studies are required to determine the most appropriate vaccine with highest protection in 
Iranian women. 
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Introduction 
Traditionally the Papanicolaou smear has been used as 
the screening method for early detection of premalignant 
lesions in cervix uterine but in view of high number of false 
negative and positive results, new molecular techniques are 
being introduced for a more sensitive and reliable approach 
and also to guide clinical decision making in approaching 
those patients with border line pathology, like those with 
ASCUS lesions in their pap test (Lytwyn et al.,2000; 
Rozendaal et al.,1996). More than 80 types of HPV have 
been characterized of which some specific types like HPV 
16 and 18 have been found to be closely related to 
pathogenesis of cervical intraepithelial neoplasia (CIN) 
(Clifford et al., 2003). Epidemiological studies are necessary 
to pave the way for better understanding and evaluating the 
risk of developing neoplasia in women who are found to be 
infected with certain types of HPVs in each population and 
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also for a precise vaccination program. According to the 
fact that there may be a localized variation in malignant 
potential of particular HPV genotypes in different 
populations (Chan et al., 2002) and in the view of widespread 
interest in HPV vaccines, we decided to organize a study to 
characterize pattern of HPV infection in Iranian women in 
two referral hospitals. During our investigation we also 
collected seven solid cervical tumors, subsequently proven 
to be squamous carcinoma of cervix, and compared the HPV 
genotypes in these end stage lesions with those we had found 
in women with normal and abnormal cervical cytology. 
Materials and Methods 
Patients and sample collection 
This study was approved by the local university ethical 
committee. From October 2005 to January 2006, 127 
outpatient women were enrolled from two gynecology 
clinics in Imam Hospital complex and Mirza Koochek-Khan 
hospital in Tehran. Our aim was to compare prevalence of 
HPV infection and identify common subtypes in normal 
women and those with abnormal Pap smear test of high-
grade squamous intraepithelial lesions (HSIL), low-grade 
squamous intraepithelial lesions (LSIL) or abnormal 
squamous celss of unknown significance (ASCUS) in their 
medical history within last year. 
Each patient was interviewed first and a comprehensive 
questionnaire containing information about identity, age at 
sexual activity onset, number of sexual partners, history of 
genital infection and important medical conditions, 
utilization of contraception, and history of previous Pap test 
was filled. We collected 50 patients with abnormal cytology 
in their previous abnormal Pap smears; the inclusion criterion 
for inclusion was a cytological report of cervical 
intraepithelial neoplasia within the last year, those referred 
for cervical biopsy and or topical treatment being excluded. 
We also collected 77 women who never had any 
cytological report in support of cervical neoplasia nor had 
HPV cytopathic effects.The third group of samples comprise 
7 cervical solid masses from 7 women who had been 
admitted in surgery ward with proven squamous cell 
carcinoma of cervix in biopsy. After exposing cervix using 
sterile speculum, epithelial cells of endocervix were collected 
by a 360 degree scrape of nylon cytobrush in transitional 
zone, and then the cells were transferred to sterile vial 
containing 5 cc of PBS (phosphate buffer saline). The vials 
containing epithelial suspension were delivered to molecular 
laboratory for DNA extraction in the same day. After 
epithelial cell sampling for molecular analysis, each patient 
underwent a conventional pap test using Ayre's Spatula and 
a smear of cervical cells was prepared on a sterile blade. 
Then, after fixation in alcohol 95% the smears were sent to 
cytology laboratory for evaluation. Those cases with 
inadequate cells for cytological investigation were excluded 
or invited for re sampling; therefore each registered case 
had a sample for molecular evaluation of HPV infection and 
a cytological file for conventional Pap test. 
Precipitation of epithelial cells and DNA extraction: 
The cell suspension were centrifuged (10min, 3000xg, 
4C) and the lysis buffer (10 m M Tris-HCL; Ph 8, 1m M 
EDTA, 1% SDS, 1 M NaCl) and the proteinase K (125 Î1⁄4g/ 
500 Î1⁄4l) Were added on the pelleted cells and incubated 
56 C for 2 hours. The standard phenol-chloroform extraction 
and the ethanol precipitation were used for DNA purification 
and the pelleted DNA was resuspended in 50-100 µ1⁄4l of 
tridistillated sterile water (Husnjak et al., 2000). In order to 
determine the quality and quantity of the isolated DNA, each 
DNA was analyzed by electrophoresis on 0.8 % agarose gels 
stained with ethidium bromide and spectrophotometrically. 
Polymerase chain reaction (PCR) 
DNA samples were amplified with the GP5+ and GP6+ 
primers targeting the L1 open reading frame of broad 
spectrum HPV genomes (Husnjak et al., 2000). In all 
samples, the constitutively expressed SRY gene was 
amplified first to confirm the adequacy of the extracted DNA 
and PCR amplification. DNA from Caski and Hella cells 
was used as positive control in all preliminary PCR runs. 
Positive samples were further analyzed with type specific 
HPV primers to identify high risk (HPV 16 and 18), 
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 Table 1. Primer Sequences for Specific HPV Genotypes, their Targets, Positive Controls and Product Sizes 
HPV type Primer sequence (5’-3’)  Size        Positive control  Region Reference 
GP6+/GP5+ Forward: TTTGTTACTGTGGTAGATAC 
Reverse: GAAAAATAAACTGTAAATCA 
142 bp Hella/caski L1 (Snijders et al.,1991) 
HPV16 Forward: CCCAGCTGTAATCATGCATGGAGA 
Reverse: GTGTGCCCATTAACAGGTCTTCCA 
253bp Caski cell line E6/E7 (Soler et al.,1991) 
HPV18 Forward: CGACAGGAACGACTCCAACGA 
Reverse: GCTGGTAAATGTTGATGATTAACT 
201bp Hella cell line E6/E7 (Soler et al.,1991) 
HPV31 Forward: ATGGTGATGTACACAACACC 
Reverse: GTAGTTGCAGGACAACTGAC 
514bp cervical scrape L1 (van den Brule et al., 1990) 
HPV33 Forward: ATGATAGATGATGTAACGCC 
Reverse: GCACACTCCATGCGTATCAG 
456bp cervical scrape E1/E2 (van den Brule et al.,1989) 
HPV6/11 Forward: TACACTGCTGGACAACATGC 
Reverse: GTGCGCAGATGGGACACAC 
302 bp cervical scrape E6/E7 -(Soler et al.,1991) 
intermediate risk (HPV 31 AND 33) and low risk HPV 6/11 
(Table1).The results of genotyping were verified by 
restriction fragment length polymorphism (RFLP) which 
used restriction enzymes BamHI, DdeI, HaeIII, HinfI, Pst I, 
RsaI and Sau 3AI (Bernard et al., 1994).CaSki cell line 
(containing a high copy number of HPV 16), HeLa cell line 
(containing HPV 18), HPV 31 positive cervical scrape, HPV 
33 positive cervical scrape and, HPV 16 and HPV 33 positive 
cervical scrape were all received from Magdalena Grce. 
Statistical analysis 
Statistical analysis was performed using SPSS 11 
software. Chi square; Student’s t-test and Mann-Whitney 
test were used to investigate intergroup significance. 
Results 
In this study we included 127 women who attended 
gynecology clinics in Tehran university hospitals. We also 
collected 7 solid cervical tumors which were subsequently 
proved to be squamous carcinoma of cervix. All 127 women 
underwent routine Pap test for cytological evaluation and at 
the same visit a sample of cervical epithelial cells was 
obtained by scraping the cervix osteum. After cytological 
evaluation and review of medical records, 50 women with 
abnormal cytology in their Pap smears were categorized in 
abnormal group and the remaining 77 women with normal 
Pap smear and no previous abnormality in their records were 
categorized in normal group. The third group comprised 7 
patients with cervical Squamous cell carcinoma.Women with 
normal cytology and those with abnormal cytology were 
similar in age (33.0 and 35.3 years, respectively P=0.52), 
adopting contraception methods (40/50 vs.55 /77, P>0.05) 
and age at beginning of sexual activity (18.2 vs. 20.2 years 
Table 2. Frequency of HPV Infection, Determined with 
the GP5+/GP6+ Primers 
Study Groups     Total  Negative Positive 
Women with abnormal cytology 50 20 (40%) 30 (60%) 
Women with cervical carcinoma  7  0 (0%)  7 (100%) 
Women with normal cytology 77 67 (87%) 10 (13%) 
Table 3. Comparison of HPV Genotypes in Different 
Pathological Grades 
Pathology Total HPV infection
(GP05/06)   16       18        31         33      6/11 
Normal  77 10 (13)*  9 (12) 0 0 0 1 (1) 
ASCUS*  31 18 (58) 11 (35) 3 (9) 0 0 2 (6) 
LSIL   12    7 (58)  5 (41) 1 (8) 0 0 1 (8) 
HSIL  7 5 (71)  5 (71) 0 0 0 0 
SCC**  7 7 (100)  6 (85) 2 (28) 1 (14) 0 0 
Total 134 47 36 6 1 0 4 
*Number (%). ASCUS=atypical squamous cells of undetermined 
significance; LSIL=Low grade squamous intraepithelial lesion HSIL= High 
grade squamous intraepithelial lesion; SCC=Squamous cell carcinoma *: 
Two samples could not be sub-typed with available specific primers. **: 
Two samples were co-infected with. HPV16, 18 and HPV16, 31.  
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respectively). None of the women reported cigarette smoking 
or having multiple sexual partners. In normal group HPV 
infection was established in 10 cases (13%), while 30(60%) 
HPV positive cases were found in patients with abnormal 
cytology and interestingly all of the 7 cancerous patients 
(100%) were positive for HPV infection which yields a 
significant relation between HPV infection and cervical 
neoplasia (P value <0.001). 
Those positive cases for HPV infection were further 
underwent subtyping using specific HPV primers. The 
frequency of different genotypes is presented in (Table 
3).Overall, the prevalence of HPV 16, 18, 11/6 and 31 in all 
infected samples was respectively 76%, 12.7%, 8% and 2%. 
All 7 tumor samples were positive for HPV general primers 
of which, 5 samples were infected with HPV 16, two samples 
were co-infected with HPV16,18 and HPV16,31 genotypes 
and one sample was infected with HPV 18. 
Discussion 
Cervical cancer is the most common malignancy among 
females in developing countries, with highest prevalence in 
Latin America, Asia and Africa (Parkin et al., 1999). 
Likewise, in Iran cervical cancer has been the most common 
cancer amongst women. The high rate of cervical cancer 
fell from 19.4% to 11.4% of all reported malignancies10 
(Mortazavi et al., 2000) mainly because of adopting 
screening methods, literally Pap test, and early detection of 
precancerous lesions. HPV plays a central role in 
pathogenesis of cervical cancer and this viral infection is 
considered to be a necessary although not always a sufficient 
cause. HPV DNA has been shown to be present in over 99% 
of cervical cancers (Walboomers et al., 1999) and it is now 
clear that persistent infection with high risk HPV increases 
the risk of developing cervical carcinoma (HO GY et al., 
1998). Recently, prophylactic (Harro et al., 2001; Koutsky 
et al., 2002) and therapeutic vaccination (IM and Monk, 
2002) have shown promising results for preventing HPV 
infection as well as cervical neoplasia. Noticeably there are 
evidences that vaccinating the subjects who were infected 
with HPV (PCR positive) can reduce the incidence of CIN 
1-3 in affected women (Olson, 2006).Development of 
effective vaccines would require a comprehensive study on 
HPV genotypes in different regions of the world. 
Worldwide, HPV 16 is the most common type followed 
by HPV18 and geographical variations in non-HPV16 
distribution have been noted (Clifford et al., 2003). To the 
best of our knowledge, there are no previously published 
studies from Iran that have investigated the prevalence of 
different HPV genotypes among women with normal and 
abnormal cervical cytology. In one study on different HPV 
genotypes in cervical cancer among Iranian women 
(Mortezavi et al., 2002), HPV16 (73.9%) and HPV18 
(11.6%) were the most common detected viruses in cervical 
tumors, followed by HPV33 .In our study, prevalence of 
HPV16 in women with proved cervical SCC, abnormal 
cytology (ASCUS, LSILAND HSIL) and those with normal 
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Pap test were 85%, 42% and 11.6% respectively. Moreover, 
HPV16 made up 76% of all HPV infections in all women in 
different groups, which makes it as the main culprit for 
cervical neoplasia in Iranian women. In addition, there was 
a meaningful relation (P value=0.013) between HPV18 
infection and pathologic cervical lesions as 2 samples of 
the 7 cervical tumors (28%) and four women with an 
abnormal Pap test (8%) were HPV18 positive while no 
HPV18 infection was detected in women with normal 
cytology. 
Among the 134 women who were enrolled in this study 
we did not find any habitual cigarette smoker or any case 
with a history of multiple sexual partners. Therefore, theses 
risk factors are not likely to be influential among the majority 
of Iranian women at the moment. There was neither 
significant difference in other risk factors including age of 
sexual activity onset, parities and using contraception 
between different groups of the study. 
According to our study high rates of infection with HPV 
genotypes in sexually active Iranian women make molecular 
investigation for HPV16 and 18 essential in clinical approach 
to patients with proved dysplasia in their screening tests and 
also to those patients with borderline or incongruous 
pathology reports. Since the vaccines have already been tried 
in humans and found to be very effective in preventing 
cervical neoplasia, their utilization will be soon justified in 
developing countries like Iran. However, it is essential to 
choose those which are compatible with prevalent 
genotypes. Further studies with larger scales of samples and 
investigation of wider spectrum of HPV genotypes are 
required to choose the best between available monovalent 
prototype HPV16 vaccine and quadrivalent ( HPV 
6,11,16,18) vaccines. 
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